GlassScriptPhysician profile
Chad J Tarabolous
NPI 1023271913
$3,199.40
in general payments reported to CMS, 2019-2025
41 companies · $345 in 2025
The $345 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $672 · 2020: $274 · 2021: $367 · 2022: $528 · 2023: $428 · 2024: $587 · 2025: $345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,359.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $546.79 | 2019-2025 | Opdivo |
| Novartis Pharmaceuticals Corporation | $358.05 | 2019-2025 | |
| Amgen INC. | $347.57 | 2019-2023 | Blincyto, Lumakras |
| Pfizer INC. | $198.55 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $184.29 | 2019-2025 | Keytruda, Lynparza |
| Gilead Sciences, INC. | $169.43 | 2019-2025 | Trodelvy |
| Celgene Corporation | $154.98 | 2021-2025 | Reblozyl |
| Amag Pharmaceuticals, INC. | $102.40 | 2019 | |
| Daiichi Sankyo INC. | $97.44 | 2022-2023 | Injectafer |
| Janssen Biotech, INC. | $91.68 | 2021-2025 | Darzalex, Tecvayli, Talvey |
| Astrazeneca Pharmaceuticals LP | $86.45 | 2019-2020 | |
| Genzyme Corporation | $66.86 | 2019-2023 | |
| Seagen INC. | $62.84 | 2019-2022 | |
| Incyte Corporation | $61.34 | 2021-2024 | Jakafi |
| Adc Therapeutics America, INC. | $59.29 | 2021-2025 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Tarabolous listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.